Viral upper respiratory tract infections are associated with increased colonization by
Gene expression profiles of Detroit-562 pharyngeal cells, which were either mock-infected or infected with human respiratory syncytial virus (RSV) or human parainfluenza virus 3 (HPIV3), were analyzed using human microarrays. Transcription response of
We have identified a core transcriptome that represents the basic machinery required for adherence of pneumococci to D562 cells infected or not infected with a virus. These bacterial genes and cell adhesion molecules can potentially be used to control pneumococcal adherence occurring secondary to a viral infection.
Viruses play a pivotal role in modulating host cells, consequently mediating bacterial superinfection [
Although several studies have demonstrated suppression of the host’s immune response as a potential mechanism for bacterial superinfection, the degree of bacterial infection induced by prior viral infection is indistinguishable from that shown using experimental models without a complete immune system e.g.
Some studies suggest that bacterial factors also play a part in this interaction, but whether or not bacteria modulate their surface structures to enhance adherence in the presence of viral infection remains controversial [
TIGR4 [
Tissue culture microtiter plates were seeded with 200 μl of a 2 × 105 D562 cells/ml suspension per well and grown for ~4 d to about 80% confluence (9.6 × 104 cells/well). Semi-confluent monolayers were washed twice with phosphate buffered saline (PBS) and inoculated with a 100 μl volume of viral suspension. To infect monolayers with RSV, the virus stock containing 6.5 × 106 TCID50/ml was diluted to 10-1 to 10-3 with minimal essential medium with Eagle's salts (EMEM) (Gibco Laboratories, Grand Island, NY, USA), supplemented with penicillin (50 μg/ml), streptomycin (50 μg/ml) and 2% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA). Each dilution of the virus was inoculated in triplicate. For HPIV3, the virus stock containing 8.3 × 107 TCID50/ml was diluted to 10-3 to 10-6 with serum-free EMEM containing penicillin (100 μg/ml), streptomycin (100 μg/ml) and supplemented with crystallized porcine trypsin. Each virus dilution was inoculated into six wells. The negative control, which constituted of the same culture medium used for viral inoculation but without the virus, was seeded in another six wells. Plates were incubated at 37°C in a 5% CO2 incubator and, at 24 h intervals after inoculation (24–72 h for RSV and 24–120 h for HPIV3), were used for pneumococcal adherence experiments as previously described [
It is worth noting that although the adherence assays in this and in the accompanying manuscript by Kimaro Mlacha et al. were performed the same way, there was one difference in the treatment of mock-infected D562 cells (cells not infected with viruses) prior to the adherence assay. For this manuscript, the D562 cells were manipulated before reaching 100% confluence. At day 4, cells were washed to allow for viral inoculation. This manipulation of the monolayer might have resulted in fewer D562 cells being present at day 6 compared than those in the accompanying manuscript, which were left intact for 6 days. Despite this difference, the mock-infected and virus-infected cells within the assay described in this manuscript were treated exactly the same way, making the comparison relevant within this experiment.
For microarray experiments, semi-confluent D562 cells grown in tissue culture flasks were either mock-infected or infected with stock virus at 6.5 × 105 TCID50 /ml for RSV and 8.3 × 103 TCID50/ml for HPIV3, and incubated at 37°C on a shaker. After 1 h of adsorption, fresh medium was added into each flask and cultures were incubated at 37°C for 3 d. The D562 cells were used for: (a) pneumococcal microarray experiments or (b) analysis of host-cell transcription profiles upon exposure to RSV or HPIV3. (a) Virus-infected and mock-infected cells were inoculated with 1 ml of pneumococcal TIGR4 strain containing 107 bacteria and incubated for 2 h at 37°C in a 5% CO2 incubator. Non-adherent bacteria (contained in the spent cell culture medium) were removed and cells were washed 3X with PBS and then treated immediately with 10 ml of RNAprotect (Qiagen, Valencia, CA, USA). Adherent bacteria were dissociated from host cells by lysis with 0.1% (w/v) saponin in PBS followed by sonication using 5 s pulses for 1 min. Bacteria were subsequently harvested by differential centrifugation. Control bacteria, which were not exposed to host cells, were suspended in EMEM medium and then prepared in parallel and treated identically to adherent bacteria. Pellets were stored at −80°C. (b) After inoculation of semi-confluent D562 cells with viruses for 3 d, the viral suspension (or un-inoculated media for mock-infected controls) was removed from the monolayer and the cells were washed twice with PBS with 0.2% BSA. Subsets of the monolayers (both mock and virus-infected) were inoculated with 1 ml of pneumococcal TIGR4 strain suspension containing 107 bacteria, and the remaining monolayers were mock-infected with EMEM. All monolayers were incubated for 2 h at 37°C in a 5% CO2 incubator then washed 2X with PBS with 0.2% BSA. D562 cells were detached by treatment with 0.025% trypsin-EDTA (Gibco Laboratories, Grand Island, NY, USA), and cell clumps were disrupted by gently pipetting up and down. The cells were collected by centrifugation at 800 x
Total RNA was isolated from: (a) RNA-stabilized bacteria adherent to either mock- or virus-infected D562 cells and bacteria growing freely in EMEM and (b) monolayers of D562 cells either mock-infected or infected with RSV or HPIV3. RNA was extracted using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA) in a lysing matrix containing silica beads on a FastPrep Instrument (MP Biomedicals, Solon, OH, USA) according to the manufacturer’s protocol. RNA was purified with the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and the quality was assessed using the prokaryote and eukaryote total RNA chips on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Bacterial microarray experiments were performed on version 6
Data were analyzed using the TM4 microarray software suite [
Reverse transcription was carried out using the QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA) in accordance with the manufacturer’s instructions. Briefly, 1 μg of total RNA was incubated in gDNA Wipeout Buffer (7X) and RNase-free water and incubated at 42°C for 2 min to remove contaminating genomic DNA. The cDNA was synthesized from the RNA using Quantiscript reverse transcriptase (RT), Quantiscript RT buffer (5X), and a primer mix at 42°C for 15 min and then at 95°C for 3 min to inactivate the Quantiscript RT. Dilutions of the cDNA (0.25 μl of the above mixture per 20 μl reaction) were used as template in a reaction containing 2X QuantiTect SYBR Green mix (Qiagen, Valencia, CA, USA), RNase-free water and gene-specific primers (Additional file
A similar procedure was used for qRT-PCR validation of pneumococcal microarray data. The primers used are listed in Additional file
D562 cells were permissive to infection with RSV and HPIV3, with discrete cytopathic effect (CPE) after 72 h but without much detachment of the monolayers hence allowing for pneumococcal adherence. We then investigated whether pneumococci adhered in greater numbers to virus-infected D562 cells than to mock-infected cells. The optimal incubation period of virus-infected cells required for maximum bacterial adherence was determined to be 72 h in a preliminary time-course experiment (data not shown). The adherence of pneumococcal strains TIGR4 and G54 to D562 cells increased significantly with prior viral infection (
To limit the number of variables being compared for the gene expression analysis, we restricted the experiments to one strain of pneumococcus, TIGR4, and one respiratory virus – HPIV3. RNA was isolated from TIGR4 in contact with HPIV3- or mock-infected D562 cells.
Compared to controls (pneumococci in cell culture medium), the gene regulation ratios for pneumococci in contact with virus- or mock-infected pharyngeal cells varied from 0.1 to 14.4. Among the 77 genes that were up-regulated, 51 were regulated in both virus-infected and mock-infected conditions (Additional file
Eight pneumococcal genes appeared in the list of genes that were up-regulated after contact with HPIV3-infected cells but were absent in the list of genes up-regulated after contact with mock-infected cells. These were:
Given the very large number of human genes and the particular hypothesis under test in this study, we focused our analysis on genes encoding cell adhesion molecules. HPIV3 infection induced the up-regulation of 55 human genes (Table
Differential expression of cell adhesion molecules
| | | | Fold change | ||||
| GB# | Gene name | Gene symbol | HPIV3-infected/mock-infected | RSV-infected/mock-infected | TIGR4-infected/mock-infected | HPIV3-TIGR4-infected/mock-infected | RSV-TIGR4-infected/mock-infected |
| AA406020 | ISG15 ubiquitin-like modifier | ISG15 | 23.80 | 1.10 | 1.05 | 24.76 | 1.15 |
| AA456886 | Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 | MX1 | 23.68 | 1.11 | 1.04 | 16.12 | 1.12 |
| AA286908 | Myxovirus (influenza virus) resistance 2 | MX2 | 13.84 | 1.06 | 1.05 | 12.35 | 1.04 |
| T95113 | Radical S-adenosyl methionine domain containing 2 | RSAD2 | 11.72 | 0.90 | 1.11 | 4.49 | 1.39 |
| AA126958 | DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 | DDX58 | 11.55 | 1.16 | 0.88 | 9.94 | 0.96 |
| AA419251 | Interferon induced transmembrane protein 1 (9-27) | IFITM1 | 7.32 | 0.96 | 0.99 | 5.88 | 0.76 |
| AA421603 | SAM domain and HD domain 1 | SAMHD1 | 5.67 | 0.96 | 0.89 | 4.80 | 0.86 |
| AI245550 | Phospholipid scramblase 1 | PLSCR1 | 5.00 | 0.91 | 0.95 | 3.36 | 1.11 |
| AA995904 | TCF3 (E2A) fusion partner | TFPT | 4.05 | 1.35 | 1.05 | 4.12 | 0.91 |
| AA827287 | Interferon-induced protein 35 | IFI35 | 3.85 | 1.10 | 0.95 | 3.40 | 1.00 |
| H54629 | Tumor necrosis factor (ligand) superfamily, member 10 | TNFSF10 | 3.64 | NA | 1.18 | 4.32 | NA |
| AA862371 | Interferon induced transmembrane protein 2 (1-8D) | IFITM2 | 3.37 | 0.85 | 0.92 | 2.18 | 0.93 |
| AA877255 | Interferon regulatory factor 7 | IRF7 | 3.25 | X | 1.06 | 2.13 | 0.71 |
| AI038270 | Eukaryotic translation initiation factor 2-alpha kinase 2 | EIF2AK2 | 2.91 | 1.11 | 0.99 | 1.56 | 1.04 |
| AA479795 | Interferon stimulated exonuclease gene 20kda | ISG20 | 2.91 | NA | 1.10 | 2.29 | NA |
| N67034 | Interferon-induced protein 44-like | IFI44L | 2.87 | 1.01 | 1.05 | 2.90 | 0.94 |
| N75384 | Peroxisome proliferator-activated receptor gamma, coactivator 1 beta | PPARGC1B | 2.45 | 0.78 | 0.94 | NA | 0.58 |
| W37864 | Phosphatase and tensin homolog | PTEN | 2.43 | 0.90 | 0.93 | 1.05 | 0.78 |
| H17861 | Ring finger protein 213 | RNF213 | 2.26 | 1.05 | 1.03 | 1.14 | 1.02 |
| AA983252 | Signal transducer and activator of transcription 2, 113kda | STAT2 | 2.23 | X | 1.12 | 1.53 | NA |
| R70479 | Tumor necrosis factor, alpha-induced protein 3 | TNFAIP3 | 2.17 | 0.75 | 1.03 | NA | 0.73 |
| AA128561 | Collagen, type XVII, alpha 1 | COL17A1 | 1.95 | 1.11 | 1.99 | 1.16 | 1.15 |
| AI016022 | NLR family, CARD domain containing 5 | NLRC5 | 1.93 | X | X | X | 0.94 |
| N70463 | B-cell translocation gene 1, anti-proliferative | BTG1 | 1.90 | 1.43 | 1.13 | NA | 1.39 |
| H61758 | ELK4, ETS-domain protein (SRF accessory protein 1) | ELK4 | 1.86 | 0.80 | 0.87 | NA | 1.03 |
| R33456 | Desmoplakin | DSP | 1.82 | 1.03 | 0.88 | 1.18 | 0.86 |
| AA609992 | Dehydrogenase/reductase (SDR family) member 9 | DHRS9 | 1.78 | 1.45 | 0.95 | 1.09 | 1.50 |
| AA136060 | Polycomb group ring finger 5 | PCGF5 | 1.74 | 0.99 | 0.96 | 1.21 | 0.82 |
| AI364513 | Scavenger receptor class B, member 2 | SCARB2 | 1.72 | 1.06 | NA | NA | 0.97 |
| AA491191 | Interferon, gamma-inducible protein 16 | IFI16 | 1.72 | 1.38 | 0.94 | 0.97 | 1.99 |
| AA451844 | Microtubule associated monoxygenase, calponin and LIM domain containing 2 | MICAL2 | 1.70 | 0.91 | 0.91 | X | 0.79 |
| R93911 | Glycogen synthase kinase 3 beta | GSK3B | 1.68 | 1.29 | NA | NA | 1.32 |
| AA776304 | Pleckstrin 2 | PLEK2 | 1.67 | 0.97 | NA | 1.81 | 1.08 |
| AA490894 | Endoplasmic reticulum aminopeptidase 1 | ERAP1 | 1.67 | 1.19 | 0.87 | X | 1.25 |
| AA777854 | Ring finger protein 12 | RNF12 | 1.67 | 0.85 | 0.99 | NA | 0.92 |
| AA040699 | ELK3, ETS-domain protein (SRF accessory protein 2) | ELK3 | 1.65 | 0.99 | 0.91 | X | 0.86 |
| H95362 | Claudin 1 | CLDN1 | 1.64 | 0.83 | NA | 1.26 | 1.20 |
| AA411757 | Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) | CEACAM1 | 1.63 | X | NA | 1.41 | 0.51 |
| AA284668 | Plasminogen activator, urokinase | PLAU | 1.63 | 1.15 | 1.27 | X | 1.25 |
| AA135422 | CCR4-NOT transcription complex, subunit 1 | CNOT1 | 1.63 | 0.99 | 0.89 | 1.04 | 1.05 |
| AI049712 | Epidermal growth factor receptor | EGFR | 1.62 | 1.00 | 0.91 | 1.13 | 0.96 |
| N70848 | Ring finger protein 141 | RNF141 | 1.58 | 1.11 | 0.94 | 1.08 | 0.90 |
| AA005112 | LIM domain 7 | LMO7 | 1.58 | 0.89 | 0.83 | 0.81 | 0.77 |
| AA488674 | Myeloid cell leukemia sequence 1 (BCL2-related) | MCL1 | 1.58 | 0.96 | X | X | 0.84 |
| AA018412 | Coiled-coil domain containing 93 | CCDC93 | 1.57 | 0.92 | 1.11 | 1.03 | 0.85 |
| AA478738 | Catenin, beta interacting protein 1 | CTNNBIP1 | 1.55 | 0.97 | 0.88 | X | 1.03 |
| AI652954 | Transglutaminase 1 (K polypeptide epidermal type I, protein-glutamine-gamma-glutamyltransferase) | TGM1 | 1.54 | 0.67 | 0.86 | 1.05 | 0.56 |
| N59721 | Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 | SERPINE2 | 1.54 | 0.69 | 0.88 | X | 0.93 |
| AA001432 | Laminin, alpha 3 | LAMA3 | 1.53 | 1.23 | 0.86 | 0.94 | 1.21 |
| AA706099 | NEDD4 binding protein 1 | N4BP1 | 1.52 | 1.08 | 1.01 | 1.19 | 0.98 |
| N33214 | Matrix metallopeptidase 14 (membrane-inserted) | MMP14 | 1.52 | 0.84 | 0.79 | 1.26 | 0.91 |
| AA406373 | Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) | TAP2 | 1.46 | 2.28 | 1.10 | 1.18 | 1.27 |
| AA620877 | Protein tyrosine phosphatase, receptor type, M | PTPRM | X | 2.11 | 1.10 | 1.18 | 1.27 |
| AA701353 | Hypothetical protein LOC92270 | LOC92270 | 0.79 | 2.07 | 0.90 | 1.34 | 2.45 |
| AA001983 | Hypothetical LOC92482 | LOC92482 | 0.83 | 1.74 | 1.08 | NA | X |
| AI014782 | Trinucleotide repeat containing 6B | TNRC6B | 1.22 | 1.99 | 1.08 | 0.86 | 1.88 |
| H80712 | Caspase 10, apoptosis-related cysteine peptidase | CASP10 | X | 1.73 | 0.79 | X | 1.84 |
| H23077 | Rho family GTPase 1 | RND1 | X | 1.71 | X | NA | 1.75 |
| AA903644 | Protocadherin beta 19 pseudogene | PCDHB19P | 0.84 | 1.65 | X | X | 1.67 |
| H01197 | Pleckstrin homology domain containing, family F (with FYVE domain) member 2 | PLEKHF2 | 0.96 | 1.63 | 0.87 | 0.87 | 1.35 |
| R36431 | Fibronectin type III domain containing 3A | FNDC3A | 1.37 | 1.62 | 0.92 | 1.03 | 1.41 |
| AA047413 | Zinc finger protein 23 (KOX 16) | ZNF23 | NA | 1.60 | 1.18 | X | 1.20 |
| AA903552 | Lysozyme-like 1, lysozyme-like 2 | LYZL1, LYZL2 | X | 1.58 | NA | NA | 1.79 |
| AA485438 | Ring finger protein 187 | RNF187 | 0.84 | 1.58 | 1.02 | 0.86 | 1.18 |
| AI168153 | Pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 8 | PLEKHA8 | X | 1.57 | X | X | 1.41 |
| AA878257 | Colony stimulating factor 1 | CSF1 | X | 1.57 | NA | NA | 1.13 |
| AI004484 | Zinc finger protein 318 | ZNF318 | X | 1.52 | 1.29 | NA | 1.62 |
| T65736 | Selenium-binding protein | SELENBP1 | 3.98 | 0.65 | 1.35 | 1.12 | NA |
| AI093729 | ADAM metallopeptidase with thrombospondin type 1 motif, 2 | ADAMTS2 | 3.87 | 1.61 | 1.59 | 0.59 | NA |
| AA443000 | Granulocyte colony stimulating factor receptor | CSF3R | 2.75 | 1.43 | 0.89 | 1.10 | 0.93 |
| AA460304 | Human ribosomal DNA complete repeating unit | CRISPLD2 | 2.58 | NA | 1.27 | NA | 0.75 |
| AI003033 | Neural cell adhesion molecule 2 | NCAM2 | 2.56 | 1.50 | 1.43 | 1.36 | 0.97 |
| AA904923 | HNF1 homeobox B | HNF1B | 2.34 | 0.65 | 1.40 | NA | 1.30 |
| AA521362 | CR2/CD21/c3d/Epstein-Barr virus receptor complement component receptor 2 | CR2 | 2.33 | NA | 1.15 | NA | 0.99 |
| T98262 | General transcription factor IIIC, polypeptide 3 | GTF3C3 | 2.33 | 0.96 | 1.50 | NA | 0.72 |
| AA904604 | RIKEN | LOC143678 | 2.21 | 1.11 | 0.80 | 1.46 | 0.95 |
| AI188215 | Neuregulin 1 | NRG1 | 2.21 | NA | 0.91 | NA | 0.80 |
| W60968 | Myelin protein zero-like protein2; Epithelial V-like antigen 1 precursor | MPZL2 | 2.19 | NA | 2.47 | NA | 0.36 |
| R88767 | Protocadherin 10; protocadherin 20 precursor | PCDH20 | 2.13 | 0.72 | 1.34 | NA | 0.81 |
| R01281 | Src kinase-associated phosphoprotein1; SKAP55 protein | SKAP55 | 1.94 | NA | 1.22 | NA | 1.17 |
| AA150694 | LY6/PLAUR domain containing 6 | LYPD6 | 1.85 | NA | 1.26 | NA | 1.08 |
| AA707615 | Chromosome 9 open reading frame 116 | C9orf116 | 1.83 | 0.73 | 1.05 | NA | 0.87 |
| H57180 | Phospholipase C-like phospholipase C, gamma 2 (phosphatidylinositol-specific) | PLCG2 | 1.82 | NA | 1.23 | NA | 1.09 |
| AA883775 | Metallaproteinase-disintegrin | ADAM30 | 1.80 | 0.32 | 1.19 | NA | 2.26 |
| AI361560 | Homeo box C9 | HOXC9 | 1.76 | 0.59 | 0.91 | 0.89 | 0.93 |
| AI380234 | C1qr(p) complement component C1q receptor | CD93 | 1.76 | 0.55 | NA | 0.56 | NA |
| R86733 | Zinc finger protein | ZNF397 | 1.74 | NA | 1.59 | NA | 1.10 |
| R08109 | Alu subfamily J sequence contamination warning entry | ZNF398 | 1.70 | 1.02 | 0.96 | 0.81 | 1.05 |
| AA176413 | F-box protein Fbx20 | FBX20 | 1.70 | 0.36 | 1.08 | NA | 1.09 |
| H90292 | Procollagen type V alpha 2 | SERPINA1 | 1.70 | 1.77 | 0.94 | 1.47 | 0.76 |
| AA680249 | Bactericidal/permeability-increasing protein | BPI | 1.69 | 1.20 | 2.06 | 1.24 | NA |
| R43755 | Intraflagellar transport protein 57 homolog | ESRRBL1 | 1.68 | 1.35 | 1.28 | 0.97 | 1.05 |
| AA620742 | Xenotropic and polytropic retrovirus receptor | XPR1 | 1.67 | 1.37 | 0.87 | 0.82 | 1.00 |
| AA137073 | Integrin, beta-like 1 (with EGF-like repeat domains) | ITGBL1 | 1.66 | 0.81 | 1.03 | 0.74 | 0.99 |
| T70368 | Integrin, beta 5 | ITGB5 | 1.66 | 1.03 | 1.09 | 1.64 | 1.01 |
| R76099 | Toll-like receptor 3 | TLR3 | 1.62 | 0.58 | 0.83 | NA | 0.85 |
| H52352 | Complement factor properdin | CFP | 1.62 | NA | 1.54 | NA | 0.54 |
| R98903 | Scavenger receptor class B, member 1 | SCARB1 | 1.59 | NA | 1.01 | NA | 0.73 |
| AA150507 | Interleukin 1, beta | IL1B | 1.59 | 1.99 | 1.81 | 1.17 | 0.56 |
| T98612 | Alpha-1 type III collagen | COL3A1 | 1.57 | 1.74 | 0.83 | NA | 1.06 |
| T52330 | Interleukin 6 receptor | IL6R | 1.57 | 1.36 | 1.06 | 1.07 | 1.17 |
| AA010600 | Nuclear RNA export factor 3 | NXF3 | 1.56 | 1.58 | 1.23 | 0.99 | 1.00 |
| AA176249 | Transforming growth factor, beta 2 | TGFB2 | 1.56 | 0.64 | 0.87 | NA | 1.18 |
| R10099 | Stabilin-2 | STAB2 | 1.56 | 0.98 | 1.10 | 1.18 | 1.21 |
| N32241 | Zinc finger protein 160 | ZNF160 | 1.55 | NA | 1.10 | NA | 1.06 |
| W94121 | Tumor necrosis factor receptor superfamily, member 19 | TNFRSF19 | 1.55 | 1.17 | 1.06 | 0.53 | 0.92 |
| H93115 | Ras association (ralgds/AF-6) and pleckstrin homology domains 1 | RAPH1 | 1.54 | 1.56 | 0.72 | 0.80 | NA |
| AA455067 | Non-Ab component of amyloid peptide precursor | SNCA | 1.54 | NA | 1.14 | NA | 0.93 |
| R68721 | Apo-2 ligand, TNF-related apoptosis inducing ligand TRAIL | TNFSF10 | 1.54 | NA | 0.83 | NA | 1.24 |
| AA456622 | Wiskott-Aldrich syndrome protein interacting protein | WIPF1 | 1.54 | NA | 1.16 | NA | 1.00 |
| H74265 | Protein tyrosine phosphatase, receptor type, C | PTPRC | 1.53 | NA | 1.15 | NA | 1.20 |
| T68892 | Secreted apoptosis related protein 2 | SFRP1 | 1.52 | NA | 0.95 | 1.17 | 1.16 |
| AA780815 | Alpha-2 type VIII collagen | COL8A2 | 1.50 | 0.98 | 1.14 | 1.43 | 0.83 |
Genes listed are up-regulated by infection with HPIV3 (A), RSV (B), and/or TIGR4 (C).
X indicates genes that did not meet the criteria established for microarray analysis (see Methods); NA indicates data points that had no single value.
Since the results above suggested that the enhanced expression of various adhesion molecules following HPIV3 and RSV infection may increase the level of adherence of pneumococci, we sought to describe the transcription profiles of cell adhesion molecules exposed to the TIGR4 strain and compared them to the virus-induced transcription profiles. We found that genes that were regulated in the presence of HPIV3 and RSV were not significantly regulated in TIGR4; rather, infection with TIGR4 alone resulted in the up-regulation of a unique set of genes (Table
A subset of differentially expressed genes from the human microarray experiments was selected and qRT-PCR analysis was undertaken to confirm the relative levels of gene expression. The experiments were performed on the same RNA samples used in microarray experiments. The correlation coefficient (R) between qRT-PCR and microarray results for pneumococcal transcription in contact with either virus-infected or mock-infected epithelial cells was 0.92 and 0.84, respectively. On the host side, the correlation coefficient between the two conditions in HPIV-3 infected cells and RSV-infected cells were 0.87 and 0.65, respectively (Additional file
In the present study, we have used a well-established model of adherence to demonstrate that infection of human pharyngeal cells with paramyxoviruses RSV or HPIV3 enhanced the adherence of
We wanted to determine whether: (i) the pneumococcus is capable of detecting and responding to the host cell changes by expressing additional factors to complement newly expressed host cell receptors on the surface of viral-infected cells, or (ii)
As enhanced adherence was observed with both pneumococcal strains and with both viruses, we focused the pneumococcal microarray experiments on one strain–virus combination. We selected TIGR4 because it exhibited greater adherence to epithelial cells than G54, and we selected HPIV3 because it expresses NA. Our observation that multiple pneumococcal adhesins are regulated upon the binding of the bacterium to both mock- and virus-infected cells suggests that there is a common set of genes whose protein products represent good targets for designing interventions to prevent pneumococcal infection in the nasopharynx.
The up-regulated operon SP_0204–SP_0206 encodes a ribonucleoside triphosphate reductase (
We hypothesized that viral infection can enhance bacterial adhesion by increasing the expression of host cell receptors. Our study supported this contention by showing that a variety of epithelial cell receptors (CEACAM1, CD47, interferon-stimulated genes, among others) were up-regulated in response to HPIV3 and RSV infection. Other studies examining this question have either focused exclusively on the expression of a small number of cell adhesion receptors, or have studied non-human epithelial cells. CEACAM1 and CD47 have previously been identified in the host cell response to viral infection [21] and we have confirmed this observation with regard to HPIV3. CEACAM1 binds meningococcal and gonococcal opacity-associated (Opa) proteins and mediates internalization of the bacteria into several cell types
Interestingly, the gene encoding a fibronectin type III domain-containing protein was up-regulated by the host in response to both viruses (significantly in RSV and moderately in HPIV3). In our pneumococcal gene expression studies, a fibronectin-binding gene,
Other genes that were significantly up-regulated in our study include several interferon-stimulated genes (ISGs) and the urokinase plasminogen activator (PLAU), which mediates a response to the inflammation induced by the virus. Induction of ISGs and NOD-like receptor family (Table
In summary, we have shown that: (a) D562 cells were permissive to RSV and HPIV3; (b) these viruses augmented the adherence of
CEACAM: Carcinoembryonic antigen-related cell adhesion molecule; CPE: Cytopathic effect; D562 cells: Detroit 562 cells; FN: Fibronectin; HCL: Hierarchical clustering; HPIV3: Human parainfluenza virus 3; ISGs: Interferon-stimulated genes; MARCO: Macrophage receptor; NA: Neuraminidase; PAFR: Platelet-activating factor; RSV: Respiratory syncytial virus; SAM: Significance analysis of microarrays.
JAGS reports receiving a grant from GlaxoSmithKline Biologicals (Anthony Scott, Kayla Laserson; $2,575,975; Oct 2010-Sep 2013) for a study entitled: ‘A phase IV multi-site observational epidemiology study to assess potential risk for adverse events following immunization that may be associated with misuse of a two-dose vial of 10-valent Pneumococcal Conjugate Vaccine (Synflorix) in Kenya’.
SZKM carried out the adherence assays and pneumococcal microarray experiments, analyzed the data and drafted the manuscript. TCTP participated in the design and performance of viral adherence assays. NK performed the human microarray experiments and qRT-PCR experiments. SRS participated in the design and performance of bacterial adherence assays and RNA extractions and drafting of the manuscript. JCDH participated in the design and analysis of all experiments involving molecular work in this manuscript. NI participated in the pneumococcal microarray experiments. VGH performed qRT-PCR experiments. DRR participated in the bioinformatics analysis of microarray work. DDE, GMC, JS participated in the design of the study. JAGS and HT conceived the study, participated in the study design and development, analysis and drafting of the manuscript. All authors read and approved this manuscript.
Click here for file
This work was supported by grants from the Wellcome Trust to Prof. Anthony Scott (081835) and University of Maryland internal funds to Dr. Hervé Tettelin. The authors wish to thank Dr. Norman Lee (George Washington University, Washington DC, USA) and the Pathogen Functional Genomics Resource Center (PFGRC) at the J. Craig Venter Institute (JCVI, Rockville, MD, USA) for providing microarray slides, Gowrisankar Rajam (Centers for Disease Control and Prevention, CDC, Atlanta, GA, USA) for technical assistance and Margaret Mackinnon and Greg Fegan (KEMRI/Wellcome Trust, Kilifi, Kenya) for expert advice on statistical methods.